The Rubella vaccine is a crucial preventive measure against rubella, also known as German measles. Rubella is caused by the rubella virus, and while it generally causes a mild illness in children and adults, it poses significant risks to pregnant women. If a pregnant woman contracts rubella, it can lead to congenital rubella syndrome (CRS), resulting in severe birth defects in the developing fetus. The rubella vaccine is typically administered as part of the measles, mumps, and rubella (MMR) vaccine, providing immunity against all three diseases. It is also available in combination with the varicella (chickenpox) vaccine in the MMRV vaccine. Vaccination efforts, particularly in childhood, have led to a substantial decrease in rubella cases globally and have played a pivotal role in preventing CRS. The vaccine is generally well-tolerated, and widespread immunization is a key strategy in public health initiatives to eliminate rubella and protect vulnerable populations. Ongoing research continues to refine vaccine strategies, monitor vaccine safety, and improve global vaccination coverage against rubella.
Khursheed Nadeem Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey